Three new #obesity drugs—high-dose semaglutide, semaglutide plus cagrilintide, and oral orforglipron—may soon be approved in the US. JAMA Medical News Director Jennifer Abbasi and Lead Senior Staff Writer Rita Rubin examine how US$ 27.12 Min. order: 1 piece ★★★★★ 4.2 (298 reviews) Sold : Login>>
Anti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance US$ 20.71 Min. order: 1 piece ★★★★★ 4.7 (205 reviews) Sold : Login>>
Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had ≥1 weight-related complication, individuals assigned to a combination US$ 21.47 Min. order: 1 piece ★★★★★ 4.5 (285 reviews) Sold : Login>>